ADVERTISEMENTREMOVE AD
×
×

DGCI

DCGI Grants Emergency Use Approval to Corbevax Vaccine for 12–18 Age Group

DCGI Grants Emergency Use Approval to Corbevax Vaccine for 12–18 Age Group

DGCI Grants Conditional Market Approval for Covaxin & Covishield

DGCI Grants Conditional Market Approval for Covaxin & Covishield
ADVERTISEMENTREMOVE AD

DGCI Gives Nod For Phase-3 Trials of Bharat Biotech’s Intranasal COVID Vaccine

DGCI Gives Nod For Phase-3 Trials of Bharat Biotech’s Intranasal COVID Vaccine

Covaxin Approved for Children Between 2-18 Yrs By Expert Panel: How Safe is It?

Covaxin Approved for Children Between 2-18 Yrs By Expert Panel: How Safe is It?
DCGI Grants Emergency Use Approval to Corbevax Vaccine for 12–18 Age Group

DCGI Grants Emergency Use Approval to Corbevax Vaccine for 12–18 Age Group

DGCI Grants Conditional Market Approval for Covaxin & Covishield

DGCI Grants Conditional Market Approval for Covaxin & Covishield

DGCI Gives Nod For Phase-3 Trials of Bharat Biotech’s Intranasal COVID Vaccine

DGCI Gives Nod For Phase-3 Trials of Bharat Biotech’s Intranasal COVID Vaccine
ADVERTISEMENTREMOVE AD